Clinical research falls within the professional, scientific, and technical services industry. More specifically, the U.S. Bureau of Labor Statistics classifies it under “Research and Development in the Physical, Engineering, and Life Sciences” (NAICS code 541710), a subset of Scientific Research and Development Services. But that formal classification only tells part of the story. Clinical research sits at the intersection of healthcare, pharmaceuticals, biotechnology, and regulatory science, making it one of the more complex industries to pin down.
Where Clinical Research Fits in the Economy
At its core, clinical research is the process of testing new drugs, medical devices, and treatments in human volunteers to determine whether they are safe and effective. This work is the bridge between a laboratory discovery and a product your doctor can prescribe. It absorbs a massive share of pharmaceutical spending: clinical trials account for roughly 68 to 69 percent of total out-of-pocket drug development costs, and the clinical phase of bringing a new drug to market lasts an average of about 95 months, compared to just 31 months for the earlier laboratory and animal testing stages.
Because of that cost and complexity, clinical research has grown into its own specialized sector within the broader life sciences industry. It employs clinical investigators, research coordinators, data managers, biostatisticians, regulatory affairs specialists, and pharmacovigilance professionals, among others. The work happens in hospitals, dedicated research sites, universities, and increasingly in patients’ own homes through remote trial designs.
The Role of Contract Research Organizations
One of the biggest segments of the clinical research industry is the contract research organization, or CRO. A CRO is a company hired by a pharmaceutical, biotech, or medical device sponsor to manage some or all of a clinical trial on the sponsor’s behalf. This lets drug companies run trials without maintaining massive in-house research teams for every study.
CROs handle a wide range of services across the entire lifecycle of a trial:
- Study design and regulatory approval: Developing trial protocols, preparing documentation, and obtaining sign-off from ethics committees and regulatory authorities.
- Site selection and patient recruitment: Identifying where the trial will run and enrolling participants who meet the study criteria.
- Monitoring and safety surveillance: Overseeing compliance with the trial protocol at each site and detecting adverse events in real time.
- Data analysis and reporting: Running the statistical analysis, producing the clinical study report, and managing the documentation that gets submitted to regulators for drug approval.
Some CROs also provide pre-clinical research services (before human testing begins) and post-marketing surveillance (after a product is already on the market). Large CROs essentially function as full-service research partners, and the industry has consolidated significantly over the past two decades as sponsors increasingly prefer outsourcing to building internal capability.
Academic Medical Centers vs. Private Research
Clinical research used to be overwhelmingly an academic enterprise. Universities and teaching hospitals ran the vast majority of industry-sponsored trials. That balance has shifted dramatically. Where academic medical centers once hosted about 80 percent of industry-sponsored clinical trials, that figure has dropped to around 40 percent. The larger share now takes place through commercial CROs and private research sites.
The shift happened for practical reasons. Commercial organizations can often start trials faster, recruit patients more efficiently, and operate at lower cost. Academic centers, meanwhile, face institutional bureaucracy, competing priorities between research and patient care, and slower administrative processes. Many academic institutions are now actively trying to recapture trial volume by streamlining their operations and partnering more strategically with industry sponsors.
Regulatory Framework
Clinical research is one of the most heavily regulated industries in existence. In the United States, the Food and Drug Administration oversees the conduct of clinical trials through a dense set of federal regulations. These cover informed consent for participants, the authority and function of Institutional Review Boards (IRBs), financial disclosure requirements for investigators, rules for handling electronic records, and the specific application processes for new drugs, biologics, and medical devices.
IRBs play a particularly important role. These independent review boards must approve any research involving human subjects before a trial can begin. They review the study protocol, the informed consent documents, and the overall risk-to-benefit profile. They also have the authority to require changes to a study design or to shut down a trial entirely if participant safety is at risk. Periodic re-review ensures ongoing oversight throughout the life of a trial.
Internationally, similar oversight comes from bodies like the European Medicines Agency and national regulatory authorities. The International Council for Harmonisation (ICH) provides globally recognized guidelines for Good Clinical Practice, which serve as the quality standard most countries reference when setting their own rules.
The Shift Toward Decentralized Trials
One of the most significant recent changes in the industry is the rise of decentralized clinical trials, or DCTs. These trials move some or all study activities away from traditional hospital or clinic sites and into participants’ homes, using tools like telemedicine visits, wearable sensors, electronic consent forms, and direct-to-patient drug shipments.
Growth in decentralized trials was already underway before 2020, with registered trials roughly doubling from 46 in 2017 to 102 in 2019. The COVID-19 pandemic then accelerated adoption sharply. When in-person site visits became difficult or impossible, sponsors and regulators had to adapt quickly. Registered decentralized trials jumped from 102 in 2019 to 189 in 2020 and continued climbing to 250 by the end of 2023. A comprehensive database search covering through early 2024 identified over 2,100 decentralized trials total.
The appeal is straightforward: decentralized approaches can reduce costs through streamlined data collection, shorten development timelines, and make it easier for patients to participate without frequent travel to a research clinic. The field is still maturing, though, with much of the current work focused on establishing reliable methods and standards for remote data collection.
Who Works in Clinical Research
The industry employs people from a wide range of backgrounds. Clinical research coordinators manage the day-to-day operations at trial sites, working directly with participants. Clinical research associates (often called monitors) travel to sites to verify that data is being collected correctly and that the protocol is being followed. Biostatisticians design the analytical framework for trials and interpret results. Regulatory affairs professionals manage submissions to agencies like the FDA. Medical monitors, usually physicians, oversee participant safety throughout a study.
Entry points vary. Research coordinators often come from nursing, biology, or health sciences backgrounds. Data management and biostatistics roles draw from mathematics and computer science. Regulatory affairs professionals may have backgrounds in pharmacy, law, or life sciences. The industry also employs large numbers of project managers, quality assurance specialists, and medical writers who translate complex trial data into the reports regulators require.
For anyone trying to understand where clinical research belongs on a job application or business classification form, the short answer is life sciences research and development. But the industry’s real identity is more practical than any code suggests: it is the business of proving whether new medical treatments actually work, conducted under strict government oversight, and funded primarily by the pharmaceutical and biotechnology companies that need that proof to bring their products to market.